Eiger BioPharmaceuticals, Inc. EIGR NASDAQ

NASDAQ Global Market • Healthcare • Biotechnology • US • USD

SharesGrow Score

35/100

1/6 Pass

SharesGrow Intrinsic Value

N/A

Negative cash flow

SharesGrow 7-Criteria Score All 7 criteria scored · valuation-related highlighted on this page

Eiger BioPharmaceuticals, Inc. (EIGR) .

本页证实的标准:

VALUE (0/100, 未通过) — 综合估值评分低于60/100的通过门槛。

SharesGrow 综合评分： 34/100 其中 1/7 项标准通过。

SharesGrow 7-Criteria Score

35/100

SG Score

View full scorecard →

—

价值

N/A

No coverage

✓

未來

100/100

Analyst consensus

→ Forecast

✗

过去

0/100

→ Income

✗

健康

0/100

Debt-to-Equity & liquidity

→ Health

护城河

50/100

→ Income

成长

48/100

→ Income

✗

收入

10/100

→ Income

估值概览 — EIGR

估值倍数

P/E (TTM)0.0

前瞻 P/EN/A

PEG 比率N/A

前瞻 PEGN/A

P/B 比率0.00

P/S 比率0.16

EV/EBITDA0.0

每股数据

EPS (TTM)$-50.78

每股账面价值$0.00

每股营收$10.68

每股自由现金流$0.00

收益率与内在价值

盈利收益率N/A

股息收益率0.00%

EPS：实际 vs 预期

P/E Ratio & Earnings Yield

每股收益 (EPS) 历史

Year	EPS（稀释）	营收	净利润	净利润率
2014	$-21.62	$0.00	$-33.85M	-
2015	$-35.11	$0.00	$-44.41M	-
2016	$-5.63	$0.00	$-47.09M	-
2017	$-4.86	$0.00	$-42.45M	-
2018	$-3.84	$0.00	$-52.39M	-
2019	$-3.01	$0.00	$-73.64M	-
2020	$-2.30	$0.00	$-68.63M	-
2021	$-0.98	$12.14M	$-33.92M	-279.3%
2022	$-69.74	$13.48M	$-96.78M	-717.7%
2023	$-50.78	$15.77M	$-74.96M	-475.3%